PH12020500613A1 - Nitrogenated heterocyclic amide compound, and use thereof for medical purposes - Google Patents
Nitrogenated heterocyclic amide compound, and use thereof for medical purposesInfo
- Publication number
- PH12020500613A1 PH12020500613A1 PH12020500613A PH12020500613A PH12020500613A1 PH 12020500613 A1 PH12020500613 A1 PH 12020500613A1 PH 12020500613 A PH12020500613 A PH 12020500613A PH 12020500613 A PH12020500613 A PH 12020500613A PH 12020500613 A1 PH12020500613 A1 PH 12020500613A1
- Authority
- PH
- Philippines
- Prior art keywords
- diabetes
- disease
- heart failure
- type
- amide compound
- Prior art date
Links
- -1 heterocyclic amide compound Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 101100463130 Arabidopsis thaliana PDK gene Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 abstract 1
- 208000005018 Hyperlactatemia Diseases 0.000 abstract 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 208000012268 mitochondrial disease Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018016328 | 2018-02-01 | ||
| PCT/JP2019/003052 WO2019151274A1 (ja) | 2018-02-01 | 2019-01-30 | 含窒素複素環アミド化合物及びその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12020500613A1 true PH12020500613A1 (en) | 2021-05-31 |
Family
ID=67479787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12020500613A PH12020500613A1 (en) | 2018-02-01 | 2020-07-14 | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10800784B2 (enExample) |
| EP (1) | EP3747888A4 (enExample) |
| JP (3) | JP7241556B2 (enExample) |
| KR (1) | KR102725118B1 (enExample) |
| CN (1) | CN111655692B (enExample) |
| AR (1) | AR114237A1 (enExample) |
| AU (1) | AU2019214048B2 (enExample) |
| BR (1) | BR112020014177A2 (enExample) |
| CA (1) | CA3090219A1 (enExample) |
| CL (1) | CL2020002003A1 (enExample) |
| CO (1) | CO2020009420A2 (enExample) |
| IL (1) | IL276386B2 (enExample) |
| MX (1) | MX2020008126A (enExample) |
| MY (1) | MY205011A (enExample) |
| PE (1) | PE20211273A1 (enExample) |
| PH (1) | PH12020500613A1 (enExample) |
| SA (1) | SA520412473B1 (enExample) |
| SG (1) | SG11202006916SA (enExample) |
| TW (1) | TWI803570B (enExample) |
| WO (1) | WO2019151274A1 (enExample) |
| ZA (1) | ZA202004548B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3851103A4 (en) | 2018-09-11 | 2022-06-08 | Japan Tobacco Inc. | THERAPEUTIC OR PROPHYLACTIC AGENT FOR CHRONIC KIDNEY DISEASE CONTAINING A PYRAZOLE-AMIDE COMPOUND |
| WO2023032940A1 (ja) | 2021-09-01 | 2023-03-09 | 日本たばこ産業株式会社 | 含窒素三環性化合物及びその医薬用途 |
| CN110407744A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种1-(4-氨基吡啶-2-基)乙酮的合成方法 |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| BR112022014749A2 (pt) * | 2020-03-04 | 2022-10-11 | Japan Tobacco Inc | Composto tricíclico fundido e uso medicinal do mesmo |
| WO2022052958A1 (en) * | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| AU2022244941B2 (en) * | 2021-03-23 | 2024-08-01 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Heterocycle substituted ketone derivative, and composition and medicinal use thereof |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7943617B2 (en) * | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| WO2008132162A1 (en) * | 2007-04-26 | 2008-11-06 | Boehringer Ingelheim International Gmbh | 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments |
| AU2008263206A1 (en) * | 2007-06-01 | 2008-12-18 | Schering Corporation | Gamma secretase modulators |
| EP2090576A1 (en) * | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| AR074797A1 (es) * | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
| MX364602B (es) * | 2011-06-27 | 2019-05-02 | Alectos Therapeutics Inc | Inhibidores selectivos de glicosidasa y usos de los mismos. |
| CA2855009C (en) * | 2011-11-15 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as gpr119 agonists |
| WO2013187646A1 (en) * | 2012-06-12 | 2013-12-19 | Chong Kun Dang Pharmaceutical Corp. | Piperidine derivatives for gpr119 agonist |
| CN103570725B (zh) | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| TWI633885B (zh) * | 2013-03-15 | 2018-09-01 | 日商日本煙草產業股份有限公司 | 吡唑－醯胺化合物及其醫藥用途 |
| TW201536748A (zh) * | 2013-07-01 | 2015-10-01 | Japan Tobacco Inc | 茀－醯胺化合物及其醫藥用途 |
| WO2015002119A1 (ja) | 2013-07-01 | 2015-01-08 | 日本たばこ産業株式会社 | ピラゾール－アルコール化合物およびその医薬用途 |
| GB201316823D0 (en) * | 2013-09-23 | 2013-11-06 | R & D Vernalis Ltd | New Chemical Entities |
| CA2933927C (en) | 2013-12-17 | 2021-11-16 | Merck Patent Gmbh | N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| CA2994027C (en) | 2015-07-31 | 2023-10-10 | Merck Patent Gmbh | Bicyclic heterocyclic derivatives |
| EP3436443B1 (en) | 2016-03-29 | 2020-03-11 | Merck Patent GmbH | N1-(3,3,3-trifluoro-2-hydroxy-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase |
| CN109071490B (zh) * | 2016-04-28 | 2021-04-06 | 默克专利股份公司 | 哌啶基衍生物 |
| EP3492452B1 (en) * | 2016-07-29 | 2022-08-31 | Japan Tobacco Inc. | Production method for pyrazole-amide compound |
| US10414774B2 (en) | 2016-08-15 | 2019-09-17 | Merck Sharp & Dohme Corp. | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease |
| LT3532064T (lt) | 2016-10-28 | 2020-09-25 | H. Lundbeck A/S | Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui |
| RU2019108717A (ru) | 2016-10-28 | 2020-11-30 | Х. Лундбекк А/С | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов |
| WO2023032940A1 (ja) * | 2021-09-01 | 2023-03-09 | 日本たばこ産業株式会社 | 含窒素三環性化合物及びその医薬用途 |
| BR112022014749A2 (pt) * | 2020-03-04 | 2022-10-11 | Japan Tobacco Inc | Composto tricíclico fundido e uso medicinal do mesmo |
-
2019
- 2019-01-30 PE PE2020001125A patent/PE20211273A1/es unknown
- 2019-01-30 EP EP19747660.9A patent/EP3747888A4/en active Pending
- 2019-01-30 KR KR1020207024426A patent/KR102725118B1/ko active Active
- 2019-01-30 MY MYPI2020003575A patent/MY205011A/en unknown
- 2019-01-30 CN CN201980010396.9A patent/CN111655692B/zh active Active
- 2019-01-30 US US16/261,792 patent/US10800784B2/en active Active
- 2019-01-30 AR ARP190100202A patent/AR114237A1/es unknown
- 2019-01-30 CA CA3090219A patent/CA3090219A1/en active Pending
- 2019-01-30 AU AU2019214048A patent/AU2019214048B2/en active Active
- 2019-01-30 SG SG11202006916SA patent/SG11202006916SA/en unknown
- 2019-01-30 TW TW108103504A patent/TWI803570B/zh active
- 2019-01-30 WO PCT/JP2019/003052 patent/WO2019151274A1/ja not_active Ceased
- 2019-01-30 JP JP2019013745A patent/JP7241556B2/ja active Active
- 2019-01-30 MX MX2020008126A patent/MX2020008126A/es unknown
- 2019-01-30 BR BR112020014177-1A patent/BR112020014177A2/pt unknown
-
2020
- 2020-07-14 PH PH12020500613A patent/PH12020500613A1/en unknown
- 2020-07-21 SA SA520412473A patent/SA520412473B1/ar unknown
- 2020-07-22 ZA ZA2020/04548A patent/ZA202004548B/en unknown
- 2020-07-29 IL IL276386A patent/IL276386B2/en unknown
- 2020-07-29 CO CONC2020/0009420A patent/CO2020009420A2/es unknown
- 2020-07-30 CL CL2020002003A patent/CL2020002003A1/es unknown
- 2020-10-08 US US17/065,679 patent/US20210284644A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034806A patent/JP2023071925A/ja not_active Ceased
- 2023-09-05 US US18/460,821 patent/US20240300952A1/en not_active Abandoned
-
2024
- 2024-06-12 JP JP2024094812A patent/JP2024116307A/ja not_active Ceased
-
2025
- 2025-02-13 US US19/052,425 patent/US20260070910A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008126A (es) | Compuesto de amida heterociclica nitrogenada y su uso para fines medicos. | |
| RU2015144182A (ru) | Пиразоламидное соединение и его применения в медицине | |
| MX2022010950A (es) | Compuesto triciclico fusionado y uso farmaceutico del mismo. | |
| JOP20210329A1 (ar) | مركبات بيرازول مزدوجة الاستبدال كمثبطات كيتو هيكسو كيناز | |
| JP2014518853A5 (enExample) | ||
| NZ716245A (en) | Fused benzoxazepinones as ion channel modulators | |
| JP2019131544A5 (enExample) | ||
| HRP20230633T1 (hr) | Supstituirani 2-azabicikli i njihova uporaba kao modulatora receptora oreksina | |
| EA201690035A1 (ru) | Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов | |
| NO20084919L (no) | Oksadiazolidindionforbindelse | |
| JP2008532974A5 (enExample) | ||
| JOP20210039B1 (ar) | مركبات بيريدين 6،2 - ديامينو | |
| FI3681857T3 (fi) | Fluorifenyyli-beeta-hydroksietyyliamiineja ja niiden käyttö hyperglykaemian hoidossa | |
| FI4464321T3 (fi) | Tetrahydropyraanilla (thp) substituoituja bisyklisiä pyrimidiinidioniyhdisteitä | |
| AR074619A1 (es) | Derivados de ciclopentilacrilamida | |
| EA201892687A1 (ru) | Кристаллическая форма соединения, подавляющего активность протеинкиназы, и её применение | |
| CO2024003629A2 (es) | Compuesto tricíclico que contiene nitrógeno y su uso farmacéutico | |
| ZA202402435B (en) | Nitrogen-containing tricyclic compound and pharmaceutical use thereof | |
| RU2018128304A (ru) | Пиразоламидное соединение и его применения в медицине | |
| EA201391314A1 (ru) | Новое фенилпиридиновое производное и содержащее его лекарственное средство | |
| WO2009048274A3 (en) | Benzofuran and benzothiophene derivatives substituted with amide, process for the preparation thereof, and pharmaceutical compositions containing the same | |
| NZ610866A (en) | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient | |
| RU2018131500A (ru) | Кристаллические модификации гидрохлорида n-(4,5-бисметансульфонил-2-метилбензоил)гуанидина и солей n-(4,5-бисметансульфонил-2-метилбензоил)гуанидина | |
| JP2019523253A5 (enExample) | ||
| HRP20130983T1 (hr) | Derivati arilciklopropilacetamida, korisni kao aktivatori glukokinaze |